• United Therapeutics flagged new data from its pivotal TETON-1 study in idiopathic pulmonary fibrosis, with results scheduled for presentation at American Thoracic Society (ATS) 2026 in Orlando on May 15-20.
• Management characterized TETON-1 findings as positive, supporting the clinical profile of inhaled treprostinil in IPF without detailing performance measures.
• Company also highlighted ADVANCE OUTCOMES, a Phase 3 trial of ralinepag in pulmonary arterial hypertension, with trial results slated for ATS 2026 presentation.
• Readouts were positioned as potentially decision-driving for development strategy across pulmonary fibrosis, interstitial lung disease, and pulmonary hypertension programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260511030304) on May 11, 2026, and is solely responsible for the information contained therein.